May 11, 2020
A key Japanese reimbursement policy panel on May 8 approved a special “mixed-billing” arrangement for Gilead Japan’s COVID-19 treatment Veklury (remdesivir) to make the drug available for free for patients while allowing them to keep their copay rates unchanged for...read more